I've noticed a few things that might be worth writing down here:
- Outstanding shares have went slightly up to 11.1 million.
- Approximately 17 traditional chinese medicines to start selling in May 2010
- JGBO tries to get as much of their products on the reimbursement list
- Management focuses on shareholder value (a little work to be done then)
- Working together with 3 institutions (for example: Shandong University)
- Operating at 70% of manufacturing capacity, in near future possible expanding (will need capital for that)
- Fully diluted 17 million shares outstanding
- Radix Dispersible Tablets growing very rapidly
- Big potential: Kang Gu Sui Yan Pian
- 3 drugs still pending final SFDA approval
- LFAA still undergoing tests and still under negotiation to acquire
- Distribution, marketing, selling throughout almost the complete country
- 11 Products from Hongrui portfolio will be introduced in phase 1
- Possible in the future: buy new products, acquire other company(s), focussing on high margin products
- Net profit margin 20.2% (Q3 2009)
Unfortunately nothing said about uplisting and/or share buyback (I find this very disturbing).
There was a little talk about the private placements (Pope and Ardsley) but I couldn't make much of it (listen to it yourself fast forward to 21 minutes or so).
Explanation on the national list of products to be reimbursed, couldn't make much of it either.
Looking at expanding into other countries. Regulations and other difficulties make it a future project.
I see I have written down a lot of things that Bigplay777 already has, hadn't read his post when I wrote this...
